Blood stem cells are usually transplanted to treat leukaemia. As a serious complication, this can trigger an immunological response in the recipient's body, known as graft-versus-host disease (GvHD). Around one third to one half of patients develop acute GvHD.
With the protexam UPA-GvHD test
as an early warning system, GvHD can be recognised 10 to 14 days before the first clinical symptoms appear. Early detection enables timely initiation of therapy and reliable monitoring of the measures taken.
